Omacetaxine mepesuccinate

Key facts

Active substance
omacetaxine mepesuccinate
Therapeutic area
Oncology
Decision number
P/138/2009
PIP number
Omacetaxine mepesuccinate
Pharmaceutical form(s)
Powder for solution for injection
Condition(s) / indication(s)
Philadelphia chromosome positive chronic myeloid leukaemia in patients who have the T315I Bcr-Abl kinase domain mutation and who are resistant to prior imatinib therapy.
Route(s) of administration
Subcutaneous use
Contact for public enquiries
ChemGenex Europe S.A.S.
E-mail: abenichou@chemgenex.com
Country: France
Phone: +33 478429526
Fax: +33 478425571
Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating